Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. (RAPH)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Clinical developments | NaN | 631 | NaN | NaN |
| Share-based compensation | NaN | 1 | 39 | 205 |
| Other segments expenses | NaN | 648 | NaN | NaN |
| Net loss | -229 | -273 | -255 | -751 |
| Interest accrued | 3 | NaN | NaN | NaN |
| Other current assets | -2 | NaN | -6 | 2 |
| Related parties | NaN | 291 | 191 | 336 |
| Other accounts payables and accrued expenses | NaN | 31 | 2 | -27 |
| Depreciation | NaN | NaN | NaN | 0 |
| Account payables and related parties | 176 | NaN | NaN | NaN |
| Net cash used in operating activities | -44 | 46 | -17 | -239 |
| Receipt of a loan | NaN | -7 | NaN | NaN |
| Proceeds from issuance of common stock and warrants | NaN | 3 | 0 | 240 |
| Advance payment on account of shares | NaN | NaN | NaN | 0 |
| Net cash provided by financing activities | NaN | -4 | 0 | 240 |
| Change in cash and cash equivalents | -44 | 42 | -17 | 1 |
| Cash and cash equivalents at the beginning of the period | 45 | 3 | 19 | NaN |
| Cash and cash equivalents at the end of the period | 1 | 45 | 3 | NaN |